Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 23, 2015 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals to Webcast 2015 Research and Development Day on April 29, 2015

REDWOOD CITY, Calif., April 23, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cell (CSC) and...
April 22, 2015 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Initiates Dosing in Randomized Phase 2 Clinical Trial of Demcizumab in Pancreatic Cancer Patients

REDWOOD CITY, Calif., April 22, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
April 21, 2015 13:00 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Presents Data on Clinical and Preclinical Anti-Cancer Stem Cell Programs at American Association for Cancer Research Annual Meeting

PHILADELPHIA and REDWOOD CITY, Calif., April 21, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem...
April 21, 2015 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Announces Abstracts Accepted for Presentation at the 2015 ASCO Annual Meeting

REDWOOD CITY, Calif., April 21, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED) will present new data related to its clinical and preclinical anti-cancer stem cell and...
April 16, 2015 06:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Presents Demcizumab Data From Phase 1b Clinical Trial in Non-Small Cell Lung Cancer Patients at the European Lung Cancer Conference

Overall Clinical Benefit Rate of 88% Prolonged Progression Free and Overall Survival Observed in a Subset of Patients Truncated Dosing Schedule Appears to Mitigate Cardiopulmonary...
April 09, 2015 16:48 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed to Present at the Needham Healthcare Conference

REDWOOD CITY, Calif., April 9, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
April 09, 2015 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed to Present Clinical Data for Demcizumab at the European Lung Cancer Conference

REDWOOD CITY, Calif., April 9, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED) will present new data from the company's Phase 1b clinical trial of demcizumab (anti-DLL4, OMP-21M18)...
April 02, 2015 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed and Lilly Enter Clinical Supply Agreement to Evaluate the Combination of Demcizumab and Alimta(R) (pemetrexed for injection) in Lung Cancer

REDWOOD CITY, Calif., April 2, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...
March 19, 2015 08:30 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed to Present Data on Multiple Anti-Cancer Stem Cell Candidates at the American Association of Cancer Research Meeting

REDWOOD CITY, Calif., March 19, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED) will present new data related to its clinical and preclinical anti-cancer stem cell and...
March 12, 2015 16:02 ET | Source: OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals Reports Full Year and Fourth Quarter 2014 Financial Results and Recent Highlights

REDWOOD CITY, Calif., March 12, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or...